These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 30660402

  • 1. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
    Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren JJGM.
    Vaccine; 2019 Feb 08; 37(7):919-925. PubMed ID: 30660402
    [Abstract] [Full Text] [Related]

  • 2. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y, Shi N, Lu Q, Yang L, Wang Z, Li L, Han H, Zheng D, Luo F, Zhang Z, Ai X.
    Hum Vaccin Immunother; 2015 Feb 08; 11(7):1648-53. PubMed ID: 26083828
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U, Assantachai P, Wasi C, Puthavathana P, Praditsuwan R.
    Viral Immunol; 2012 Dec 08; 25(6):471-6. PubMed ID: 23061793
    [Abstract] [Full Text] [Related]

  • 4. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014 May 01; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.
    PLoS One; 2013 May 01; 8(8):e70866. PubMed ID: 23976960
    [Abstract] [Full Text] [Related]

  • 7. A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.
    Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-Ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ.
    Vaccine; 2017 Nov 01; 35(46):6290-6296. PubMed ID: 28992975
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Abitay R, Nurpeisova A, Sagymbay A, Koshemetov Z, Stukova M, Buzitskaya Z, Кulmagambetov I, Karabayeva D, Davlyatshin T, Khairullin B.
    J Med Virol; 2018 Jan 01; 90(1):41-49. PubMed ID: 28842994
    [Abstract] [Full Text] [Related]

  • 9. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015 Jan 01; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 10. Vaccination against influenza in patients with systemic sclerosis.
    Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, Braun Y, Anouk M, Kaufman I, Paran D, Caspi D, Elkayam O.
    Clin Exp Rheumatol; 2012 Jan 01; 30(2 Suppl 71):S7-11. PubMed ID: 22409886
    [Abstract] [Full Text] [Related]

  • 11. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U, Wongsurakiat P, Pooruk P, Maranetra N, Puthavathana P.
    Viral Immunol; 2010 Jun 01; 23(3):329-34. PubMed ID: 20565296
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 13. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
    Ott U, Sauerbrei A, Lange J, Schäfler A, Walther M, Wolf G, Wutzler P, Zell R, Krumbholz A.
    Med Microbiol Immunol; 2012 Aug 21; 201(3):297-302. PubMed ID: 22350187
    [Abstract] [Full Text] [Related]

  • 14. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 15. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).
    Tackenberg B, Schneider M, Blaes F, Eienbröker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Müller HH, Sommer N.
    EBioMedicine; 2018 Feb 22; 28():143-150. PubMed ID: 29337134
    [Abstract] [Full Text] [Related]

  • 16. A randomized, controlled, blinded study of the safety, immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people.
    Li S, Li L, Ai X, Yang L, Bai Y, Wang Z, Han H, Lu Q, Luo F, Zhang Z, Liu C, Xiao J, Shi N.
    Hum Vaccin Immunother; 2014 Feb 22; 10(3):557-65. PubMed ID: 24301228
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 22; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 18. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P.
    Vaccine; 2017 Dec 19; 35(52):7339-7346. PubMed ID: 29157960
    [Abstract] [Full Text] [Related]

  • 19. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W.
    Vaccine; 2006 Jun 19; 24(25):5371-80. PubMed ID: 16713661
    [Abstract] [Full Text] [Related]

  • 20. Declining responsiveness to influenza vaccination with progression of human pregnancy.
    Schlaudecker EP, Ambroggio L, McNeal MM, Finkelman FD, Way SS.
    Vaccine; 2018 Jul 25; 36(31):4734-4741. PubMed ID: 29941326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.